Pyxis Oncology, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Pyxis Oncology, Inc. (PYXS) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $1.50 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-13
- Pyxis Oncology, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $1.40, a 42.86% increase year-over-year.
- Pyxis Oncology, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $0.98, a 75.19% decline year-over-year.
- Pyxis Oncology, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $3.95, a 1.50% decline year-over-year.
- Pyxis Oncology, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $4.01, a 49.62% decline year-over-year.
- Pyxis Oncology, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $1.36, a 44.49% decline from fiscal 2024.
- Pyxis Oncology, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $2.45, a 31.02% increase from fiscal 2023.
- Pyxis Oncology, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $1.87, a 53.94% decline from fiscal 2022.
- Pyxis Oncology, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $4.06, a 59.88% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.50 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | $1.40 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | $1.36 10-K · filed 2026-03-23 | |||
| 2025-09-30 | $1.16 10-Q · filed 2025-11-03 | |||
| 2025-06-30 | $0.99 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $0.98 10-Q · filed 2025-05-15 | |||
| 2024-12-31 | $2.45 10-K · filed 2025-03-18 | |||
| 2024-09-30 | $3.89 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $3.90 10-Q · filed 2024-08-14 | |||
| 2024-03-31 | $3.95 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | $1.87 10-K · filed 2024-03-21 | |||
| 2023-09-30 | $1.97 10-Q · filed 2023-11-07 | |||
| 2023-06-30 | $3.82 10-Q · filed 2023-08-11 | |||
| 2023-03-31 | $4.01 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $4.06 10-K · filed 2023-03-22 | |||
| 2022-09-30 | $4.24 10-Q · filed 2022-11-01 | |||
| 2022-06-30 | $6.24 10-Q · filed 2022-08-15 | |||
| 2022-03-31 | $7.96 10-Q · filed 2022-05-13 | |||
| 2021-12-31 | $10.12 10-K · filed 2022-03-29 | |||
| 2021-09-30 | $6.38 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |